TY - JOUR
T1 - Treatment of hypereosinophilic syndromes-the first 100 years
AU - Butterfield, J. H.
AU - Weiler, C. R.
PY - 2012/4
Y1 - 2012/4
N2 - Treatment of the hypereosinophilic syndrome (HES) has advanced rapidly and prevention of end organ damage previously associated with the disorders is now possible in most patients who have had a timely diagnosis. Tried and true medications such as prednisone, hydroxyurea, and interferon-alpha (IFN-aα) continue to play a valuable role in treating HES and their cost is modest. Newer medications included pegylated forms of IFN-aα and IFN-α2b, first- and second-generation tyrosine kinase inhibitors (imatinib mesylate, nilotinib), and monoclonal antibodies to interleukin (IL)-5 and CD52. The combination of better understanding of HES and better medications now provide the clinician with an improved ability to control unregulated proliferation of eosinophils.
AB - Treatment of the hypereosinophilic syndrome (HES) has advanced rapidly and prevention of end organ damage previously associated with the disorders is now possible in most patients who have had a timely diagnosis. Tried and true medications such as prednisone, hydroxyurea, and interferon-alpha (IFN-aα) continue to play a valuable role in treating HES and their cost is modest. Newer medications included pegylated forms of IFN-aα and IFN-α2b, first- and second-generation tyrosine kinase inhibitors (imatinib mesylate, nilotinib), and monoclonal antibodies to interleukin (IL)-5 and CD52. The combination of better understanding of HES and better medications now provide the clinician with an improved ability to control unregulated proliferation of eosinophils.
UR - http://www.scopus.com/inward/record.url?scp=84858772703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858772703&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2012.01.001
DO - 10.1053/j.seminhematol.2012.01.001
M3 - Article
C2 - 22449628
AN - SCOPUS:84858772703
SN - 0037-1963
VL - 49
SP - 182
EP - 191
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - 2
ER -